<DOC>
	<DOC>NCT00174239</DOC>
	<brief_summary>The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.</brief_summary>
	<brief_title>Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.</brief_title>
	<detailed_description>The trial was terminated prematurely June 26, 2005 due to the inability to re-supply study drug for the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<criteria>Idiopathic Parkinson Disease Must be experiencing sleep akinesia Current treatment with other dopamine agonists Nocturnal hallucinations Dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>